More on cetuximab in head and neck cancer.
Mell
Loren K
LK
Weichselbaum
Ralph R
RR
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D000068818:Cetuximab; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000276:immunology*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab